Long-term neurodevelopment outcome of caffeine versus aminophylline therapy for apnea of prematurity

S. Khurana, M. Shivakumar, G. V. Sujith Kumar Reddy, P. Jayashree, Y. Ramesh Bhat, L. E.S. Lewis, Shashikala

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

OBJECTIVE: Methylxanthines are the most commonly prescribed drug in neonatal setups. However, Clinicians show indecision in choosing the right agent for Apnea of Prematurity in most of the developing countries. Present study aimed to compare rate of mortality and survival with normal neurodevelopment outcome at 18 to 24 months of corrected age, between Caffeine- and Aminophylline-treated infants for apnea of prematurity. METHODS: 240 infants were randomly allocated to caffeine and aminophylline for apnea of prematurity during February 2012 to January 2015. Long-term neurodevelopmental assessment was done only from children who had attained corrected age of 18 to 24 months during April 2014 to February 2016. Cognitive, language and motor deficits were assessed by Bayley Scale of infant and toddler development (BSID -III). Postnatal characteristics such as hearing and visual impairments during NICU stay were noted and same were followed up. RESULTS: Infants allocated to caffeine group showed 83% less risk of getting cognitive impairment (RR 0.16; CI 95% range 0.02 to 1.36), 50% less risk of developing motor deficits (RR 0.50; CI 95% range 0.12 to 1.95) and 24% less risk of developing language problems (RR 0.76; CI 95% range 0.36 to 1.58). However in all the neurodevelopment domains the difference between groupswas not statistically significant. Risk of mortality in caffeine groupwas 9%less over aminophylline group which was statistically non-significant (RR - 0.92; CI 95% range - 0.45 to 1.84; p = 0.81). Physical growth parameters were found to be similar in both the groups. Risk of developing visual abnormality and hearing impairments was also statistically non-significant between the groups. CONCLUSION: Caffeine and aminophylline showed similar effects in reducing the rate of mortality and improving the survival without neurodevelopment delays; though the clinical significance of caffeine over aminophylline cannot be undermined.

Original languageEnglish
Pages (from-to)355-362
Number of pages8
JournalJournal of Neonatal-Perinatal Medicine
Volume10
Issue number4
DOIs
Publication statusPublished - 01-01-2017

Fingerprint

Aminophylline
Apnea
Caffeine
Vision Disorders
Hearing Loss
Mortality
Language
Therapeutics
Child Development
Developing Countries
Survival Rate
Growth
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health

Cite this

@article{88cb6c9fcc684bd6b45f951f7aebea54,
title = "Long-term neurodevelopment outcome of caffeine versus aminophylline therapy for apnea of prematurity",
abstract = "OBJECTIVE: Methylxanthines are the most commonly prescribed drug in neonatal setups. However, Clinicians show indecision in choosing the right agent for Apnea of Prematurity in most of the developing countries. Present study aimed to compare rate of mortality and survival with normal neurodevelopment outcome at 18 to 24 months of corrected age, between Caffeine- and Aminophylline-treated infants for apnea of prematurity. METHODS: 240 infants were randomly allocated to caffeine and aminophylline for apnea of prematurity during February 2012 to January 2015. Long-term neurodevelopmental assessment was done only from children who had attained corrected age of 18 to 24 months during April 2014 to February 2016. Cognitive, language and motor deficits were assessed by Bayley Scale of infant and toddler development (BSID -III). Postnatal characteristics such as hearing and visual impairments during NICU stay were noted and same were followed up. RESULTS: Infants allocated to caffeine group showed 83{\%} less risk of getting cognitive impairment (RR 0.16; CI 95{\%} range 0.02 to 1.36), 50{\%} less risk of developing motor deficits (RR 0.50; CI 95{\%} range 0.12 to 1.95) and 24{\%} less risk of developing language problems (RR 0.76; CI 95{\%} range 0.36 to 1.58). However in all the neurodevelopment domains the difference between groupswas not statistically significant. Risk of mortality in caffeine groupwas 9{\%}less over aminophylline group which was statistically non-significant (RR - 0.92; CI 95{\%} range - 0.45 to 1.84; p = 0.81). Physical growth parameters were found to be similar in both the groups. Risk of developing visual abnormality and hearing impairments was also statistically non-significant between the groups. CONCLUSION: Caffeine and aminophylline showed similar effects in reducing the rate of mortality and improving the survival without neurodevelopment delays; though the clinical significance of caffeine over aminophylline cannot be undermined.",
author = "S. Khurana and M. Shivakumar and {Sujith Kumar Reddy}, {G. V.} and P. Jayashree and {Ramesh Bhat}, Y. and Lewis, {L. E.S.} and Shashikala",
year = "2017",
month = "1",
day = "1",
doi = "10.3233/NPM-16147",
language = "English",
volume = "10",
pages = "355--362",
journal = "Journal of Neonatal-Perinatal Medicine",
issn = "1934-5798",
publisher = "IOS Press",
number = "4",

}

Long-term neurodevelopment outcome of caffeine versus aminophylline therapy for apnea of prematurity. / Khurana, S.; Shivakumar, M.; Sujith Kumar Reddy, G. V.; Jayashree, P.; Ramesh Bhat, Y.; Lewis, L. E.S.; Shashikala.

In: Journal of Neonatal-Perinatal Medicine, Vol. 10, No. 4, 01.01.2017, p. 355-362.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Long-term neurodevelopment outcome of caffeine versus aminophylline therapy for apnea of prematurity

AU - Khurana, S.

AU - Shivakumar, M.

AU - Sujith Kumar Reddy, G. V.

AU - Jayashree, P.

AU - Ramesh Bhat, Y.

AU - Lewis, L. E.S.

AU - Shashikala,

PY - 2017/1/1

Y1 - 2017/1/1

N2 - OBJECTIVE: Methylxanthines are the most commonly prescribed drug in neonatal setups. However, Clinicians show indecision in choosing the right agent for Apnea of Prematurity in most of the developing countries. Present study aimed to compare rate of mortality and survival with normal neurodevelopment outcome at 18 to 24 months of corrected age, between Caffeine- and Aminophylline-treated infants for apnea of prematurity. METHODS: 240 infants were randomly allocated to caffeine and aminophylline for apnea of prematurity during February 2012 to January 2015. Long-term neurodevelopmental assessment was done only from children who had attained corrected age of 18 to 24 months during April 2014 to February 2016. Cognitive, language and motor deficits were assessed by Bayley Scale of infant and toddler development (BSID -III). Postnatal characteristics such as hearing and visual impairments during NICU stay were noted and same were followed up. RESULTS: Infants allocated to caffeine group showed 83% less risk of getting cognitive impairment (RR 0.16; CI 95% range 0.02 to 1.36), 50% less risk of developing motor deficits (RR 0.50; CI 95% range 0.12 to 1.95) and 24% less risk of developing language problems (RR 0.76; CI 95% range 0.36 to 1.58). However in all the neurodevelopment domains the difference between groupswas not statistically significant. Risk of mortality in caffeine groupwas 9%less over aminophylline group which was statistically non-significant (RR - 0.92; CI 95% range - 0.45 to 1.84; p = 0.81). Physical growth parameters were found to be similar in both the groups. Risk of developing visual abnormality and hearing impairments was also statistically non-significant between the groups. CONCLUSION: Caffeine and aminophylline showed similar effects in reducing the rate of mortality and improving the survival without neurodevelopment delays; though the clinical significance of caffeine over aminophylline cannot be undermined.

AB - OBJECTIVE: Methylxanthines are the most commonly prescribed drug in neonatal setups. However, Clinicians show indecision in choosing the right agent for Apnea of Prematurity in most of the developing countries. Present study aimed to compare rate of mortality and survival with normal neurodevelopment outcome at 18 to 24 months of corrected age, between Caffeine- and Aminophylline-treated infants for apnea of prematurity. METHODS: 240 infants were randomly allocated to caffeine and aminophylline for apnea of prematurity during February 2012 to January 2015. Long-term neurodevelopmental assessment was done only from children who had attained corrected age of 18 to 24 months during April 2014 to February 2016. Cognitive, language and motor deficits were assessed by Bayley Scale of infant and toddler development (BSID -III). Postnatal characteristics such as hearing and visual impairments during NICU stay were noted and same were followed up. RESULTS: Infants allocated to caffeine group showed 83% less risk of getting cognitive impairment (RR 0.16; CI 95% range 0.02 to 1.36), 50% less risk of developing motor deficits (RR 0.50; CI 95% range 0.12 to 1.95) and 24% less risk of developing language problems (RR 0.76; CI 95% range 0.36 to 1.58). However in all the neurodevelopment domains the difference between groupswas not statistically significant. Risk of mortality in caffeine groupwas 9%less over aminophylline group which was statistically non-significant (RR - 0.92; CI 95% range - 0.45 to 1.84; p = 0.81). Physical growth parameters were found to be similar in both the groups. Risk of developing visual abnormality and hearing impairments was also statistically non-significant between the groups. CONCLUSION: Caffeine and aminophylline showed similar effects in reducing the rate of mortality and improving the survival without neurodevelopment delays; though the clinical significance of caffeine over aminophylline cannot be undermined.

UR - http://www.scopus.com/inward/record.url?scp=85040114754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040114754&partnerID=8YFLogxK

U2 - 10.3233/NPM-16147

DO - 10.3233/NPM-16147

M3 - Article

VL - 10

SP - 355

EP - 362

JO - Journal of Neonatal-Perinatal Medicine

JF - Journal of Neonatal-Perinatal Medicine

SN - 1934-5798

IS - 4

ER -